🇺🇸 FDA
Pipeline program

STRO-002

TSL-B2276-1-01

Phase 2 mab completed

Quick answer

STRO-002 for Neoplasm Malignant is a Phase 2 program (mab) at SUTRO BIOPHARMA, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
SUTRO BIOPHARMA, INC.
Indication
Neoplasm Malignant
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials